Department of Pathology and Laboratory Medicine, Calgary Laboratory Services, Calgary, Alberta, Canada.
BJU Int. 2010 Aug;106(3):304-15. doi: 10.1111/j.1464-410X.2010.09499.x.
Although 'insignificant' prostate cancer has been examined separately in radical prostatectomy (RP) and radical cystoprostatectomy (RCP) studies, it is not entirely clear whether cancers designated as 'insignificant' on RP and RCP represent the same, similar or different forms of prostate cancer. Insignificant prostate cancer has been traditionally defined based on the pathological findings in the whole prostate gland. In addition to the pathological determinants of 'insignificant' prostate cancer, it is also important to account for the biological and the clinical context of the disease, as well as patient age and health status to designate a prostate cancer 'insignificant'. This review examines and compares prostate cancers described as 'insignificant' on RP and RCP. We conclude that in most cases these low-volume/low-grade prostate cancers represent an early stage and clinically 'silent' disease, which are only detected in different clinical settings.
尽管在根治性前列腺切除术(RP)和根治性膀胱前列腺切除术(RCP)研究中已经分别检查了“不显著”的前列腺癌,但尚不清楚在 RP 和 RCP 上被指定为“不显著”的癌症是否代表相同、相似或不同形式的前列腺癌。不显著的前列腺癌传统上是根据整个前列腺中的病理发现来定义的。除了“不显著”前列腺癌的病理决定因素外,还必须考虑疾病的生物学和临床背景,以及患者的年龄和健康状况,以指定前列腺癌“不显著”。这篇综述检查和比较了在 RP 和 RCP 上被描述为“不显著”的前列腺癌。我们的结论是,在大多数情况下,这些低体积/低级别前列腺癌代表了一种早期且临床上“无声”的疾病,仅在不同的临床环境中检测到。